{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:21:46Z","timestamp":1788873706499,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40265-025-02246-1","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:40:09Z","timestamp":1758793209000},"page":"1521-1534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["JAK Inhibitors for the Treatment of Vitiligo: Current Evidence and Emerging Therapeutic Potential"],"prefix":"10.1007","volume":"85","author":[{"given":"C\u00e9sar","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"issue":"5","key":"2246_CR1","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s13555-020-00447-y","volume":"10","author":"L Migayron","year":"2020","unstructured":"Migayron L, Boniface K, Seneschal J. Vitiligo, from physiopathology to emerging treatments: a review. Dermatol Ther. 2020;10(5):1185\u201398. https:\/\/doi.org\/10.1007\/s13555-020-00447-y.","journal-title":"Dermatol Ther"},{"issue":"1","key":"2246_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/phpp.12598","volume":"37","author":"JM Bae","year":"2021","unstructured":"Bae JM, Jeong KH, Choi CW, Park JH, Lee HJ, Kim HJ, et al. Development of evidence-based consensus on critical issues in the management of patients with vitiligo: a modified delphi study. Photodermatol Photoimmunol Photomed. 2021;37(1):3\u201311. https:\/\/doi.org\/10.1111\/phpp.12598.","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"4","key":"2246_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/phpp.12321","volume":"33","author":"TF Mohammad","year":"2017","unstructured":"Mohammad TF, Silpa-Archa N, Griffith JL, Lim HW, Hamzavi IH. Home phototherapy in vitiligo. Photodermatol Photoimmunol Photomed. 2017;33(4):241\u201352. https:\/\/doi.org\/10.1111\/phpp.12321.","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"8","key":"2246_CR4","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/jamadermatol.2019.0696","volume":"155","author":"JH Lee","year":"2019","unstructured":"Lee JH, Kwon HS, Jung HM, Lee H, Kim GM, Yim HW, et al. Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(8):929\u201338. https:\/\/doi.org\/10.1001\/jamadermatol.2019.0696.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"2246_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00403-020-02121-x","volume":"313","author":"Y Dong","year":"2021","unstructured":"Dong Y, Yang Q, Guo B, Zhu J, Sun X. The effects of tacrolimus plus phototherapy in the treatment of vitiligo: a meta-analysis. Arch Dermatol Res. 2021;313(5):461\u201371. https:\/\/doi.org\/10.1007\/s00403-020-02121-x.","journal-title":"Arch Dermatol Res"},{"issue":"7","key":"2246_CR6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/ajd.14353","volume":"65","author":"R Russell","year":"2024","unstructured":"Russell R, Daniel BS. A narrative review of the literature: the role of biologics and JAK inhibitors in vitiligo. Australas J Dermatol. 2024;65(7):539\u201349. https:\/\/doi.org\/10.1111\/ajd.14353.","journal-title":"Australas J Dermatol"},{"key":"2246_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2020.1712358","author":"A Vojvodic","year":"2020","unstructured":"Vojvodic A, Karagaiah P, Valle Y, Sigova J, Zerbinati N, Vojvodic P, et al. Emerging drugs for the treatment of vitiligo. Expert Opin Emerg Drugs. 2020. https:\/\/doi.org\/10.1080\/14728214.2020.1712358.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"3","key":"2246_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4103\/ds.DS-D-23-00054","volume":"41","author":"P-C Shen","year":"2023","unstructured":"Shen P-C, Tsai T-F, Lai Y-J, Liu T-L, Ng C-Y. From zero to one: Recent advances in the pathogenesis, diagnosis, and treatment of vitiligo. Dermatol Sin. 2023;41(3):133\u201344. https:\/\/doi.org\/10.4103\/ds.DS-D-23-00054.","journal-title":"Dermatol Sin"},{"key":"2246_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7710","author":"JM Richmond","year":"2018","unstructured":"Richmond JM, Strassner JP, Zapata L Jr., Garg M, Riding RL, Refat MA, et al. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Sci Transl Med. 2018. https:\/\/doi.org\/10.1126\/scitranslmed.aam7710.","journal-title":"Sci Transl Med"},{"key":"2246_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417306","volume":"24","author":"J Perez-Bootello","year":"2023","unstructured":"Perez-Bootello J, Cova-Martin R, Naharro-Rodriguez J, Segurado-Miravalles G. Vitiligo: pathogenesis and new and emerging treatments. Int J Mol Sci. 2023;24:17306. https:\/\/doi.org\/10.3390\/ijms242417306.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"2246_CR11","doi-asserted-by":"publisher","first-page":"11429","DOI":"10.3390\/ijms222111429","volume":"22","author":"P Custurone","year":"2021","unstructured":"Custurone P, Di Bartolomeo L, Irrera N, Borgia F, Altavilla D, Bitto A, et al. Role of cytokines in vitiligo: pathogenesis and possible targets for old and new treatments. Int J Mol Sci. 2021;22(21):11429. https:\/\/doi.org\/10.3390\/ijms222111429.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2246_CR12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3390\/ijms19051509","volume":"19","author":"A Bishnoi","year":"2018","unstructured":"Bishnoi A, Parsad D. Clinical and molecular aspects of vitiligo treatments. Int J Mol Sci. 2018;19(5):1509. https:\/\/doi.org\/10.3390\/ijms19051509.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2246_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jdermsci.2023.12.008","volume":"113","author":"S Inoue","year":"2024","unstructured":"Inoue S, Suzuki T, Sano S, Katayama I. JAK inhibitors for the treatment of vitiligo. J Dermatol Sci. 2024;113(1):86\u201392. https:\/\/doi.org\/10.1016\/j.jdermsci.2023.12.008.","journal-title":"J Dermatol Sci"},{"issue":"11","key":"2246_CR14","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1111\/jdv.19162","volume":"37","author":"G Tavoletti","year":"2023","unstructured":"Tavoletti G, Avallone G, Conforti C, Roccuzzo G, Maronese CA, Mattioli MA, et al. Topical ruxolitinib: a new treatment for vitiligo. J Eur Acad Dermatol Venereol. 2023;37(11):2222\u201330. https:\/\/doi.org\/10.1111\/jdv.19162.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"2246_CR15","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1016\/j.jid.2022.05.1093","volume":"142","author":"AG Pandya","year":"2022","unstructured":"Pandya AG, Harris JE, Lebwohl M, Hamzavi IH, Butler K, Kuo FI, et al. Addition of narrow-band UVB phototherapy to ruxolitinib cream in patients with vitiligo. J Investig Dermatol. 2022;142(12):3352\u20135. https:\/\/doi.org\/10.1016\/j.jid.2022.05.1093.","journal-title":"J Investig Dermatol"},{"issue":"7","key":"2246_CR16","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.23812\/j.biol.regul.homeost.agents.20233707.339","volume":"37","author":"M Kamalska","year":"2023","unstructured":"Kamalska M, Karczewski M, Nikita ET, Poggiali S, Olisova O, Lomonosov KM, et al. Vitiligo: novel treatment modalities. Small molecule inhibitors and cytokine-targeted treatments. J Biol Regul Homeostatic Agents. 2023;37(7):3421\u201330. https:\/\/doi.org\/10.23812\/j.biol.regul.homeost.agents.20233707.339.","journal-title":"J Biol Regul Homeostatic Agents"},{"issue":"Supplement_2","key":"2246_CR17","doi-asserted-by":"publisher","first-page":"ii66","DOI":"10.1093\/bjd\/ljad498.067","volume":"190","author":"A Wolkerstorfer","year":"2024","unstructured":"Wolkerstorfer A, Gooderham MJ, Sebastian M, Rosmarin D, Blauvelt A, Shayesteh Alam M, et al. Efficacy of prolonged ruxolitinib cream treatment for vitiligo among patients with limited or no initial response at 6 months. Br J Dermatol. 2024;190(Supplement_2):ii66\u20138. https:\/\/doi.org\/10.1093\/bjd\/ljad498.067.","journal-title":"Br J Dermatol"},{"key":"2246_CR18","unstructured":"National Library of Medicine. A study to evaluate the efficacy and safety of ruxolitinib cream in children (6 to < 12 years old) with nonsegmental vitiligo (NCT06072183). ClinicalTrials.gov. 2025. https:\/\/clinicaltrials.gov\/study\/NCT06804811. Accessed 19 Mar 2025."},{"key":"2246_CR19","unstructured":"National Library of Medicine. Promoting repigmentation after epidermal cell suspension grafting and preventing the loss of melanocytes using topical ruxolitinib for vitiligo in resistant areas (PREVENT) (NCT05872477). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05872477. Accessed 19 Mar 2025."},{"key":"2246_CR20","unstructured":"National Library of Medicine. A study of ATI-50002 topical solution for the treatment of vitiligo (NCT03468855). 2025. https:\/\/clinicaltrials.gov\/study\/NCT03468855. Accessed 19 Mar 2025."},{"issue":"Supplement_2","key":"2246_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae266.027","volume":"191","author":"Y Yamaguchi","year":"2024","unstructured":"Yamaguchi Y, Peeva E, Adiri R, Ghosh P, Napatalung L, Hamzavi IH, et al. Response to ritlecitinib with or without narrow band ultraviolet B (nbUVB) add-on therapy in patients with active non-segmental vitiligo (NSV). Br J Dermatol. 2024;191(Supplement_2):ljae266.027. https:\/\/doi.org\/10.1093\/bjd\/ljae266.027.","journal-title":"Br J Dermatol"},{"key":"2246_CR22","unstructured":"National Library of Medicine. A 52-week study of ritlecitinib oral capsules in adults and adolescents with nonsegmental vitiligo (active and stable) Tranquillo (Tranquillo) (NCT05583526). ClinicalTrials.gov. 2025. https:\/\/clinicaltrials.gov\/study\/NCT05583526. Accessed 19 Mar 2025."},{"key":"2246_CR23","unstructured":"National Library of Medicine. A 104-week study of ritlecitinib oral capsules in adults with nonsegmental vitiligo (active and stable) Tranquillo 2 (Tranquillo 2) (NCT06072183). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06072183. Accessed 19 Mar 2025."},{"key":"2246_CR24","unstructured":"National Library of Medicine. A 52-week study to learn about the safety and effects of ritlecitinib in participants with nonsegmental vitiligo (Tranquillo LTE) (NCT06163326). ClinicalTrials.gov. 2025. https:\/\/clinicaltrials.gov\/study\/NCT06163326. Accessed 19 Mar 2025"},{"issue":"8","key":"2246_CR25","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/ijd.17157","volume":"63","author":"A Utama","year":"2024","unstructured":"Utama A, Wijesinghe R, Thng S. Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review. Int J Dermatol. 2024;63(8):1020\u201335. https:\/\/doi.org\/10.1111\/ijd.17157.","journal-title":"Int J Dermatol"},{"key":"2246_CR26","doi-asserted-by":"publisher","first-page":"102665","DOI":"10.1016\/j.eclinm.2024.102655","volume":"73","author":"T Passeron","year":"2024","unstructured":"Passeron T, Ezzedine K, Hamzavi I, van Geel N, Schlosser BJ, Wu X, et al. Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study. eClin Med. 2024;73:102665. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102655.","journal-title":"eClin Med"},{"key":"2246_CR27","unstructured":"National Library of Medicine. A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo (Viti-Up) (NCT06118411). 2025. https:\/\/clinicaltrials.gov\/study\/NCT06118411. Accessed 19 Mar 2025."},{"key":"2246_CR28","unstructured":"National Library of Medicine. Efficacy of upadacitinib after NECS in vitiligo. ClinicalTrials.gov (NCT06454461). 2025. https:\/\/clinicaltrials.gov\/study\/NCT06454461. Accessed 19 Mar 2025."},{"issue":"Suppl. 2","key":"2246_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae266.094","volume":"191","author":"AG Pandya","year":"2024","unstructured":"Pandya AG, Ezzedine K, Passeron T, van Geel N, Brown K, Santos L, et al. Efficacy and safety of povorcitinib for extensive vitiligo: 52-week results from a double-blinded, placebo-controlled, dose-ranging phase 2b study. Br J Dermatol. 2024;191(Suppl. 2):ljae266.094. https:\/\/doi.org\/10.1093\/bjd\/ljae266.094.","journal-title":"Br J Dermatol"},{"key":"2246_CR30","unstructured":"National Library of Medicine. (2025, March 19). A study to evaluate efficacy and safety of povorcitinib in participants with nonsegmental vitiligo (STOP-V1). ClinicalTrials.gov. 2025. https:\/\/clinicaltrials.gov\/study\/NCT06113445. Accessed 19 Mar 2025."},{"key":"2246_CR31","unstructured":"National Library of Medicine. A study to evaluate efficacy and safety of povorcitinib in participants with nonsegmental vitiligo (STOP-V2). ClinicalTrials.gov. 2025. https:\/\/clinicaltrials.gov\/study\/NCT06113471. Accessed 19 Mar 2025."},{"issue":"1","key":"2246_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/srt.13642","volume":"30","author":"A Jafarzadeh","year":"2024","unstructured":"Jafarzadeh A, PourMohammad A, Khosravi M, Amiri S, Rasouli A, Keramati H, et al. A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo. Skin Res Technol. 2024;30(1):e13642. https:\/\/doi.org\/10.1111\/srt.13642.","journal-title":"Skin Res Technol"},{"key":"2246_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12237486","volume":"12","author":"V Pala","year":"2023","unstructured":"Pala V, Ribero S, Quaglino P, Mastorino L. Updates on potential therapeutic approaches for vitiligo: Janus kinase inhibitors and biologics. J Clin Med. 2023;12:7486. https:\/\/doi.org\/10.3390\/jcm12237486.","journal-title":"J Clin Med"},{"key":"2246_CR34","unstructured":"Seneschal J, Mathilde G, Merhi R, Andreu N, Cazenave S, Ezzedine K, Mazereeuw-Hautier J, Passeron T. Efficacy and safety of the combination of oral Baricitinib and NB-UVB for the treatment of active vitiligo: results from a randomized, double-blind, phase 2 proof of concept study. Abstract no. 6493, European Academy of Dermatology and Venereology (EADV) Congress 2023. 2023."},{"key":"2246_CR35","unstructured":"National Library of Medicine. Evaluation safety ,efficacy baricitinib plus excimer light versus excimer light alone in non segmental vitiligo. ClinicalTrials.gov (NCT05950542). 2025. https:\/\/clinicaltrials.gov\/study\/NCT05950542. Accessed 19 Mar 2025."},{"key":"2246_CR36","unstructured":"National Library of Medicine. Vitiligo, new treatment and serum s100B (NCT06768840). ClinicalTrials.gov. 2025. https:\/\/clinicaltrials.gov\/study\/NCT06768840. Accessed 19 Mar 2025."},{"issue":"10","key":"2246_CR37","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","volume":"151","author":"BG Craiglow","year":"2015","unstructured":"Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol. 2015;151(10):1110\u20132. https:\/\/doi.org\/10.1001\/jamadermatol.2015.1520.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"2246_CR38","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamadermatol.2017.5778","volume":"154","author":"SR Kim","year":"2018","unstructured":"Kim SR, Heaton H, Liu LY, King BA. Rapid repigmentation of vitiligo using tofacitinib plus low-dose, narrowband UV-B phototherapy. JAMA Dermatol. 2018;154(3):370\u20131. https:\/\/doi.org\/10.1001\/jamadermatol.2017.5778.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2246_CR39","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","volume":"77","author":"LY Liu","year":"2017","unstructured":"Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017;77(4):675-682.e1. https:\/\/doi.org\/10.1016\/j.jaad.2017.05.043.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2246_CR40","doi-asserted-by":"publisher","first-page":"503","DOI":"10.4103\/idoj.IDOJ_474_18","volume":"10","author":"S Sonthalia","year":"2019","unstructured":"Sonthalia S, Aggarwal P. Oral tofacitinib: contemporary appraisal of its role in dermatology. Indian Dermatol Online J. 2019;10(5):503\u201318. https:\/\/doi.org\/10.4103\/idoj.IDOJ_474_18.","journal-title":"Indian Dermatol Online J"},{"key":"2246_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.06.006","author":"A Dev","year":"2025","unstructured":"Dev A, Vinay K, Bishnoi A, Kumaran MS, Mehta H, Parsad D. Oral tofacitinib in comparison with dexamethasone oral mini-pulse therapy for the treatment of active nonsegmental vitiligo: a randomized controlled trial. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.06.006. (Published online 10 July 2025).","journal-title":"J Am Acad Dermatol"},{"key":"2246_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/life14091127","volume":"14","author":"GG Mitroi","year":"2024","unstructured":"Mitroi GG, Mitroi GF, Ic\u0103 OM, Anghelina F, Ciolofan MS, Mitroi MR. Off-label uses of abrocitinib: review of emerging therapeutic applications beyond atopic dermatitis. Life. 2024;14:1127. https:\/\/doi.org\/10.3390\/life14091127.","journal-title":"Life"},{"key":"2246_CR43","unstructured":"National Library of Medicine. Vitiligo treatment by targeting TYK2 mediated responses (ViTYK) (NCT06327321). 2025. https:\/\/clinicaltrials.gov\/study\/NCT06327321. Accessed 19 Mar 2025."},{"issue":"1","key":"2246_CR44","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/bjd\/ljad304","volume":"190","author":"Q Marin Dit Bertoud","year":"2023","unstructured":"Marin Dit Bertoud Q, Bertold C, Ezzedine K, Pandya AG, Cherel M, Castillo Mart\u00ednez A, et al. Reliability and agreement testing of a new automated measurement method to determine the extent of facial vitiligo using standardized ultraviolet images and a dedicated algorithm. Br J Dermatol. 2023;190(1):62\u20139. https:\/\/doi.org\/10.1093\/bjd\/ljad304.","journal-title":"Br J Dermatol"},{"key":"2246_CR45","doi-asserted-by":"crossref","unstructured":"King B, Eleftheriadou V, Bristow CC, Conrad DM, Elbuluk N, Wolkerstorfer A, Lui H, Yue E, Ofori S, Passeron T, Hamzavi I. A comparison of the risk of major cardiovascular events, venous thromboembolism, serious infections, and malignancies among patients with vitiligo in the United States using real-world data (Poster No. 63465). Poster presented at the American Academy of Dermatology Annual Meeting, Orange County Convention Center, Orlando, FL; 2025.","DOI":"10.1016\/j.jaad.2025.05.037"},{"key":"2246_CR46","unstructured":"National Library of Medicine. A study to compare the efficacy and safety of SCENESSE and narrow-band ultraviolet (NB-UVB) light versus NB-UVB light alone in patients with vitiligo (NCT06109649). https:\/\/clinicaltrials.gov\/study\/NCT06109649. Accessed 19 Mar 2025"},{"issue":"1","key":"2246_CR47","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamadermatol.2014.1875","volume":"151","author":"HW Lim","year":"2015","unstructured":"Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015;151(1):42\u201350. https:\/\/doi.org\/10.1001\/jamadermatol.2014.1875.","journal-title":"JAMA Dermatol"},{"key":"2246_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.16468","author":"H Pourriyahi","year":"2024","unstructured":"Pourriyahi H, Hosseini N-S, Nooshabadi MP, Pourriahi H, Baradaran HR, Abtahi-Naeini B, et al. Utility of prostaglandin analogues and phosphodiesterase inhibitors as promising last resorts for the treatment of vitiligo: a systematic review, from mechanisms of action to mono-, combination, and comparative therapies. J Cosmet Dermatol. 2024. https:\/\/doi.org\/10.1111\/jocd.16468.","journal-title":"J Cosmet Dermatol"},{"key":"2246_CR49","doi-asserted-by":"publisher","first-page":"6438","DOI":"10.1038\/s41598-023-32591-8","volume":"13","author":"N Silpa-Archa","year":"2023","unstructured":"Silpa-Archa N, Likittanasombat S, Apinuntham C, Pruksaeakanan C, Charoenpipatsin N, Chaiyabutr C, et al. The efficacy of bimatoprost ophthalmic solution combined with NB-UVB phototherapy in non-segmental and segmental vitiligo: a single-blind randomized controlled study. Sci Rep. 2023;13:6438. https:\/\/doi.org\/10.1038\/s41598-023-32591-8.","journal-title":"Sci Rep"},{"issue":"7","key":"2246_CR50","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jid.2019.11.031","volume":"140","author":"A Khemis","year":"2020","unstructured":"Khemis A, Fontas E, Moulin S, Montaudi\u00e9 H, Lacour J-P, Passeron T. Apremilast in combination with narrowband UVB in the treatment of vitiligo: a 52-week monocentric prospective randomized placebo-controlled study. J Investig Dermatol. 2020;140(7):1533\u20137. https:\/\/doi.org\/10.1016\/j.jid.2019.11.031.","journal-title":"J Investig Dermatol"},{"key":"2246_CR51","unstructured":"National Library of Medicine. Efficacy and safety of apremilast in combination with NBUVB and NBUVB alone in vitiligo patients (NCT06593197). 2025. https:\/\/clinicaltrials.gov\/study\/NCT06593197. Accessed 19 Mar 2025."},{"issue":"3","key":"2246_CR52","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/exd.14436","volume":"31","author":"N Saki","year":"2022","unstructured":"Saki N, Ghayur ES, Heiran A, Gholami M, Alipour S. Topical pentoxifylline can be an effective and safe adjunctive therapy to NBUVB therapy in treating vitiligo: a split-side clinical trial. Exp Dermatol. 2022;31(3):255\u20136. https:\/\/doi.org\/10.1111\/exd.14436.","journal-title":"Exp Dermatol"},{"key":"2246_CR53","unstructured":"National Library of Medicine. A study to evaluate the efficacy, safety, and pharmacokinetics of VYN201 gel in subjects with non-segmental vitiligo (NCT06493578). 2025. https:\/\/clinicaltrials.gov\/study\/NCT06493578. Accessed 19 Mar 2025."},{"key":"2246_CR54","unstructured":"National Library of Medicine. Evaluation of AMG 714 for vitiligo (REVEAL) (NCT04338581). 2025. https:\/\/clinicaltrials.gov\/study\/NCT04338581. Accessed 19 Mar 2025."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02246-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02246-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02246-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:34:14Z","timestamp":1763044454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02246-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2246"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02246-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"25 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C\u00e9sar Ferreira has no conflicts of interest. Brett King has served on advisory boards and\/or is a consultant and\/or is a clinical trial investigator and\/or is on a data monitoring committee for Abbvie, AltruBio Inc., Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Aquestive, Aslan Pharmaceuticals, Bristol Meyers Squibb, Concert Pharmaceuticals Inc., Eli Lilly and Company, Equillium, Galderma, GSK, Horizon Therapeutics, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Merck, Novartis, Otsuka\/Visterra Inc., Pfizer Inc., Q32 Bio Inc., Regeneron, Sanofi Genzyme, Soterios, Sun Pharmaceutical, Takeda, TWi Biotechnology Inc., and Ventyx Biosciences Inc. He has served on speaker bureaus for Abbvie, Incyte, Eli Lilly, Pfizer, Regeneron, and Sanofi Genzyme. He is a scientific advisor for BiologicsMD. Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, and UCB. Tiago Torres is an Editorial Board member of\n                      Drugs\n                      . Tiago Torres was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed equally to the idea for the article, conception, drafting, and revision of the manuscript. All authors approved the final version of the article.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}